THIS ANNOUNCEMENT CONTAINS INSIDE
INFORMATION WITHIN THE MEANING OF THE EU MARKET ABUSE REGULATION
NO.596/2014
Arix Bioscience
plc
Autolus announces
launch of proposed public offering in the
United States
LONDON, 9 April 2019: Arix Bioscience plc (LSE:ARIX)
("Arix"), a global venture capital company focused on investing in
and building breakthrough biotech companies, today notes that its
portfolio company Autolus Therapeutics plc (NASDAQ: AUTL)
(“Autolus”), has filed a registration statement on Form F-1 with
the U.S. Securities and Exchange Commission (the “SEC”) relating to
a proposed underwritten public offering in the United States of its American Depositary
Shares (“ADSs”), each ADS representing one ordinary share.
The proposed maximum aggregate offering amount specified in the
filing is 4,000,000 ADSs, which does not include the underwriters’
option to purchase 600,000 additional ADSs. The final price per ADS
in the offering will be determined following a book building
process.
The registration statement can be accessed through the SEC’s
EDGAR database.
This announcement does not constitute an offer to sell or the
solicitation of an offer to buy securities, and shall not
constitute an offer, solicitation or sale in any jurisdiction in
which such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of that
jurisdiction.
The securities referred to in this announcement are to be
offered only by means of a prospectus. When available, copies of
the preliminary prospectus can be obtained from Goldman Sachs &
Co. LLC, Attention: Prospectus Department, 200 West Street,
New York, NY 10282, or by
telephone at +1 866 471 2526 or by email at
prospectus-ny@ny.email.gs.com; or Jefferies LLC, Attention: Equity
Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor,
New York, NY 10022, or by
telephone at +1 877 821 7388 or by email at
Prospectus_Department@Jefferies.com. For the avoidance of doubt,
such prospectus will not constitute a "prospectus" for the purposes
of Directive 2003/71/EC (and amendments thereto, including
Directive 2010/73/EU, to the extent implemented in each relevant EU
member state) and will not have been reviewed by any competent
authority in any EU member state.
ENDS
Enquiries
For more information on Arix, please contact:
Arix Bioscience plc
Charlotte Parry, Head of Investor
Relations
+44 (0)20 7290 1072
charlotte@arixbioscience.com
Optimum Strategic Communications
Mary Clark, Supriya Mathur
T: +44 (0) 203 922 0891
optimum.arix@optimumcomms.com
Forward looking statements:
This announcement contains certain forward-looking statements
with respect to the portfolio companies of Arix Bioscience plc.
These statements and forecasts involve risk and uncertainty because
they relate to events and depend upon circumstances that may or may
not occur in the future. There are a number of factors that could
cause actual results or developments to differ materially from
those expressed or implied by these forward-looking statements and
forecasts. Nothing in this announcement should be construed as a
profit forecast.
About Arix Bioscience plc
Arix Bioscience plc is a global venture capital company focused
on investing in and building breakthrough biotech companies around
cutting edge advances in life sciences. We collaborate with
exceptional entrepreneurs and provide the capital, expertise and
global networks to help accelerate their ideas into important new
treatments for patients. As a listed company, we are able to bring
this exciting growth phase of our industry to a broader range of
investors. For more information please
visit www.arixbioscience.com
About Autolus
Autolus is a biopharmaceutical company developing
next-generation programmed T cell therapies for the treatment of
cancer.